Poly Medicure Limited , a leading medical equipment manufacturer, has reported no deviations in the utilization of funds raised through its Qualified Institutions Placement (QIP) for the quarter ended June 30, 2025. The company's Audit Committee reviewed the fund utilization at its meeting held on August 8, 2025, confirming adherence to the stated objectives in the placement document.

QIP Details and Fund Allocation

Poly Medicure had successfully raised Rs 99,999.98 lakh by allotting 53,19,148 equity shares to qualified institutional buyers at Rs 1,880.00 per share. The net proceeds, after accounting for issue expenses, amounted to Rs 98,534.37 lakh. These funds were earmarked for three primary purposes:

1. Funding capital expenditure for manufacturing facilities
2. Pursuing inorganic initiatives
3. General corporate purposes

Utilization Progress

As of June 30, 2025, the company has utilized Rs 12,772.45 lakh of the total funds raised. The breakdown of the utilization is as follows:

Monitoring and Transparency

CRISIL Ratings Limited, appointed as the monitoring agency, has overseen the fund utilization process. The company has maintained transparency by submitting regular reports and disclosures as per SEBI regulations.

Deployment of Unutilized Proceeds

The unutilized funds, amounting to Rs 85,761.92 lakh, have been strategically deployed to ensure optimal returns while maintaining liquidity:

• Rs 84,632.29 lakh invested in mutual funds
• Rs 800.00 lakh placed in fixed deposits with Bajaj Finance and HDFC Bank
• Rs 329.63 lakh maintained in the monitoring account

Management Commentary

Avinash Chandra, Company Secretary of Poly Medicure Limited, stated, "We are pleased to report that the utilization of QIP funds is progressing as per our planned objectives. The company remains committed to transparent and efficient use of these funds to drive our growth initiatives and enhance shareholder value."

Upcoming Investor Meetings

In related news, Poly Medicure has announced a series of upcoming investor meetings:

• August 14, 2025: Physical meeting with New Vernon Capital at the company's registered office
• August 19, 2025: Virtual call with Motilal Oswal Asset Management
• August 20, 2025: Physical meeting with Aberdeen Investments SG at the company's registered office

These meetings underscore the company's commitment to maintaining open lines of communication with its investors and analysts.

Poly Medicure , a key player in the medical devices industry, has significantly revised its export growth projections, signaling potential challenges in the global market.

Revised Export Outlook

The company has announced a substantial reduction in its export growth guidance, adjusting the projected range from the previously estimated 15-18% to a more conservative 5-10%. This downward revision represents a notable shift in Poly Medicure's export expectations for the near future.

Implications for Investors

This adjustment in export growth projections could have several implications:

1. Market Conditions: The lowered guidance might reflect changing dynamics in the global medical devices market or specific challenges faced by Poly Medicure in its key export markets.

2. Revenue Impact: With exports being a significant contributor to the company's overall revenue, this reduced growth projection may potentially impact Poly Medicure's financial performance in the coming periods.

3. Strategic Shifts: The company may need to reassess its export strategies or explore new markets to compensate for the reduced growth expectations in its current export segments.

4. Investor Sentiment: This news could influence investor sentiment and potentially affect the company's stock performance in the short term.

While the revised guidance indicates a more cautious outlook, it's important to note that Poly Medicure still anticipates positive export growth, albeit at a lower rate than previously expected. The company's ability to navigate these challenges and potentially identify new growth opportunities will be crucial for its performance in the coming quarters.

Investors and market analysts will likely be keen to hear more details from Poly Medicure's management regarding the factors behind this revision and any strategies being implemented to address the changed export outlook.